NCT04517851View on ClinicalTrials.gov

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Myelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary Myelofibrosis
Interventions
BIOLOGICAL

Elotuzumab

Given IV

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER